Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

Kotani, Daisuke; Kuboki, Yasutoshi; Horasawa, Satoshi; Kaneko, Asumi; Nakamura, Yoshiaki; Kawazoe, Akihito; Bando, Hideaki; Taniguchi, Hiroya; Shitara, Kohei; Kojima, Takashi; Tsuji, Akihito; Yoshino, Takayuki

doi:10.21203/rs.2.13999/v3

Cited by 1 publication

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, grade 3 or 4 neutropenia occurred in 38.9-72.0% of all cases. The clinical outcomes of the present study were comparable to previous reports (11,14,(16)(17)(18)(19)(20). A summary of previous prospective and retrospective reports of FTD/TPI monotherapy for patients with mCRC is presented in Table SIII (5,6,(21)(22)(23)(24)(25)(26)(27)(28).…”

Section: Resultssupporting

confidence: 86%

“…Moreover, clinical data from the phase I/II C-TASK FORCE study and the phase II study conducted by Pfeiffer et al (11,14) showed that treatment with FTD/TPI + Bev induced promising antitumor activity with manageable toxicity in advanced mCRC refractory or intolerant to standard therapies. A summary of previous prospective and retrospective reports of FTD/TPI + Bev FTD/TPI monotherapy (Tables ⅤI and SⅢ) (5,6,11,14,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). Furthermore, the clinical outcomes of FTD/TPI + Bev of this study were comparable to previous reports.…”

Section: Discussionsupporting

confidence: 83%

“…Thus, FTD/TPI + Bev may be a more effective regimen than FTD/TPI monotherapy. On the other hand, the incidence of grade 3 or 4 CIN of FTD/TPI + Bev is higher than FTD/TPI monotherapy (Tables ⅤI and SⅢ) (5,6,11,14,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). CIN was an independent predictive factor for the efficacy of FTD/TPI monotherapy, as reported previously (11,(30)(31)(32).…”

Section: Discussionsupporting

confidence: 80%

“…The DCR in patients with grade 3 or 4 CIN within the first cycle of treatment was higher than in patients without grade 3 or 4 CIN (61.5 and 38.2%, P=0.07; Table Ⅲ). (11,14,(16)(17)(18)(19)(20). In these reports, the median PFS time was 3.7-6.8 months and the median OS time was 8.6-14.4 months.…”

Section: Resultsmentioning

confidence: 86%

“…for patients with mCRC receiving salvage-line therapy is shown in Table VI(11,14,(16)(17)(18)(19)(20). The clinical outcomes such as PFS, OS, and DCR in patients treated with the FTD/TPI + Bev are better than those in patients treated with the…”

mentioning

confidence: 99%

See 4 more Smart Citations

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab

et al. 2021

View full text Add to dashboard Cite

Trifluridine (FTD)/tipiracil (TPI) plus bevacizumab (Bev) is a promising late-line treatment in metastatic colorectal cancer (mCRC). Although chemotherapy-induced neutropenia (CIN) is a well-known predictor of FTD/TPI efficacy, whether CIN is a predictive marker of efficacy for FTD/TPI + Bev remains unclear. Thus, the present study aimed to investigate the clinical outcomes of FTD/TPI + Bev and the predictive markers of its efficacy. Clinical data of patients with mCRC who received FTD/TPI + Bev at the Cancer Institute Hospital between January 2017 and August 2020 were retrospectively collected. Disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety were assessed. In addition, subgroup analyses of prognostic and predictive efficacy markers were performed. In total, 94 patients (median age, 60.0 years; age range, 32–82 years; 37 men and 57 women) were included in the present study. The DCR was 44.7%, the median PFS time was 2.9 months (2.3–4.1 months) and the median OS time was 10.0 months (7.3–11.1 months). Grade 3 or 4 CIN within the first cycle of treatment occurred in 27.7% of patients, which was significantly associated with a longer PFS time than those who did not develop CIN [3.8 months (2.3–8.4 months) vs. 2.7 months (1.8–4.0 months); P=0.008]. Furthermore, the DCR was higher in patients with grade 3 or 4 CIN within the first cycle of treatment than those without CIN (61.5 vs. 38.2%; P=0.07). Multivariate Cox regression analysis revealed that grade 3 or 4 CIN within the first cycle of treatment are independent predictors for a longer PFS time (P=0.01). Taken together, the results of the present study suggest that grade 3 or 4 CIN within the first cycle of treatment are early predictors of the efficacy of FTD/TPI + Bev.

show abstract